Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes

British Journal of Haematology

Volumn 138, Issue 4, 2007, Pages 517-526

  Lim, Zi Yi ^a   Pearce, Laurence ^a   Ho, Aloysius Y ^a   Barber, Linda ^a   Ingram, Wendy ^a   Usai, Monica ^a   Tobal, Khalid ^a   Devereux, Stephen ^a   Pagliuca, Antonio ^a   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Alemtuzumab; Myelodysplastic syndromes; Reduced intensity conditioning; T cell chimaerism

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD3 ANTIGEN; CYCLOSPORIN A; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHIMERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34447341170     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06676.x     Document Type: Article

References (31)

1. Antin, J.H., Childs, R., Filipovich, A.H., Giralt, S., Mackinnon, S., Spitzer, T. Weisdorf, D. (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 7, 473 485.
2. Bader, P., Beck, J., Frey, A., Schlegel, P.G., Hebarth, H., Handgretinger, R., Einsele, H., Niemeyer, C., Benda, N., Faul, C., Kanz, L., Niethammer, D. Klingebiel, T. (1998) Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplantation, 21, 487 495.
3. Balon, J., Halaburda, K., Bieniaszewska, M., Reichert, M., Bieniaszewski, L., Piekarska, A., Pawlowski, R. Hellmann, A. (2005) Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplantation, 35, 1083 1088.
4. Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frere, P., Bours, V., Fillet, G. Beguin, Y. (2003) T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation, 76, 1705 1713.
5. Baron, F., Baker, J.E., Storb, R., Gooley, T.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Heimfeld, S., Oparin, D., Zellmer, E., Radich, J.P., Grumet, F.C., Blume, K.G., Chauncey, T.R. Little, M.T. (2004) Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 104, 2254 2262.
6. Baron, F., Maris, M.B., Sandmaier, B.M., Storer, B.E., Sorror, M., Diaconescu, R., Woolfrey, A.E., Chauncey, T.R., Flowers, M.E., Mielcarek, M., Maloney, D.G. Storb, R. (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology, 23, 1993 2003.
7. van Besien, K., Artz, A., Smith, S., Cao, D., Rich, S., Godley, L., Jones, D., Del Cerro, P., Bennett, D., Casey, B., Odenike, O., Thirman, M., Daugherty, C., Wickrema, A., Zimmerman, T., Larson, R.A. Stock, W. (2005) Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology, 23, 5728 5738.
8. Bretagne, S., Vidaud, M., Kuentz, M., Cordonnier, C., Henni, T., Vinci, G., Goossens, M. Vernant, J.P. (1987) Mixed blood chimerism in T cell-depleted bone marrow transplant recipients: evaluation using DNA polymorphisms. Blood, 70, 1692 1695.
9. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 1071 1078.
10. Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E.J., Carter, C., Bahceci, E., Young, N.S. Barrett, A.J. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 94, 3234 3241.
11. D'Sa, S., Peggs, K., Pizzey, A., Verfuerth, S., Thuraisundaram, D., Watts, M., White, H., Hale, G., Waldmann, H., Goldstone, A., Mackinnon, S. Yong, K. (2003) T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. British Journal of Haematology, 123, 309 322.
12. Dey, B.R., McAfee, S., Colby, C., Sackstein, R., Saidman, S., Tarbell, N., Sachs, D.H., Sykes, M. Spitzer, T.R. (2003) Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation, 9, 320 329.
13. Domenig, C., Sanchez-Fueyo, A., Kurtz, J., Alexopoulos, S.P., Mariat, C., Sykes, M., Strom, T.B. Zheng, X.X. (2005) Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. Journal of Immunology, 175, 51 60.
14. Hill, R.S., Petersen, F.B., Storb, R., Appelbaum, F.R., Doney, K., Dahlberg, S., Ramberg, R. Thomas, E.D. (1986) Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood, 67, 811 816.
15. Ho, A.Y., Pagliuca, A., Kenyon, M., Parker, J.E., Mijovic, A., Devereux, S. Mufti, G.J. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 104, 1616 1623.
16. Huss, R., Deeg, H.J., Gooley, T., Bryant, E., Leisenring, W., Clift, R., Buckner, C.D., Martin, P., Storb, R. Appelbaum, F.R. (1996) Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplantation, 18, 767 776.
17. Lamba, R., Abella, E., Kukuruga, D., Klein, J., Savasan, S., Abidi, M.H., Mohamed, A. Peres, E. (2004) Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia, 18, 1681 1686.
18. Lim, Z.Y., Ho, A.Y., Ingram, W., Kenyon, M., Pearce, L., Czepulkowski, B., Devereux, S., Duarte, R.F., Pagliuca, A. Mufti, G.J. (2006) Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. British Journal of Haematology, 135, 201 209.
19. Mackinnon, S., Barnett, L., Bourhis, J.H., Black, P., Heller, G. O'Reilly, R.J. (1992) Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood, 80, 3235 3241.
20. Mapara, M.Y., Kim, Y.M., Wang, S.P., Bronson, R., Sachs, D.H. Sykes, M. (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood, 100, 1903 1909.
21. Marks, D.I., Lush, R., Cavenagh, J., Milligan, D.W., Schey, S., Parker, A., Clark, F.J., Hunt, L., Yin, J., Fuller, S., Vandenberghe, E., Marsh, J., Littlewood, T., Smith, G.M., Culligan, D., Hunter, A., Chopra, R., Davies, A., Towlson, K. Williams, C.D. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 100, 3108 3114.
22. Montero, A., Savani, B.N., Kurlander, R., Read, E.J., Leitman, S.F., Childs, R., Solomon, S.R. Barrett, A.J. (2005) Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. British Journal of Haematology, 130, 733 739.
23. Parker, J.E., Shafi, T., Pagliuca, A., Mijovic, A., Devereux, S., Potter, M., Prentice, H.G., Garg, M., Yin, J.A., Byrne, J., Russell, N.H. Mufti, G.J. (2002) Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. British Journal of Haematology, 119, 144 154.
24. Peggs, K.S., Thomson, K., Hart, D.P., Geary, J., Morris, E.C., Yong, K., Goldstone, A.H., Linch, D.C. Mackinnon, S. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, 1548 1556.
25. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 3121 3127.
26. Petz, L.D., Yam, P., Wallace, R.B., Stock, A.D., de Lange, G., Knowlton, R.G., Brown, V.A., Donis-Keller, H., Hill, L.R. Forman, S.J. (1987) Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood, 70, 1331 1337.
27. Schaap, N., Schattenberg, A., Mensink, E., Preijers, F., Hillegers, M., Knops, R., Pennings, A., Boezeman, J., Geurts van Kessel, A., de Pauw, B. de Witte, T. (2002) Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia, 16, 13 21.
28. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756 763.
29. Sullivan, K.M., Agura, E., Anasetti, C., Appelbaum, F., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J. Loughran, T. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology, 28, 250 259.
30. Sykes, M., Shimizu, I. Kawahara, T. (2005) Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance. Transplantation, 79, S28 S29.
31. Tauro, S., Craddock, C., Peggs, K., Begum, G., Mahendra, P., Cook, G., Marsh, J., Milligan, D., Goldstone, A., Hunter, A., Khwaja, A., Chopra, R., Littlewood, T., Peniket, A., Parker, A., Jackson, G., Hale, G., Cook, M., Russell, N. Mackinnon, S. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 23, 9387 9393.